Dosing and rate of administration for adults with Dermatomyositis (DM) 4
The dose may need to be individualised for each patient dependent on the clinical response. Dose based on body-weight may require adjustment in underweight and overweight patients. In over-weight patients dose should be based on the physiological standard bodyweight4
The initial infusion rate should be maintained for 30 minutes, and if tolerated, the infusion rate may be gradually increased every 30 minutes to a maximum of 4 mg/kg/min (0.04 mL/kg/min) as tolerated 4 †
Patients with DM are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 0.04 mL/kg/min4
Ensure that patients with pre-existing renal insufficiency are not volume depleted. For patients at risk of renal dysfunction or thromboembolic events, administer octagam®10% at the minimum infusion rate practicable, not to exceed 3.3 mg/kg/min (0.03 mL/kg/min). Discontinue octagam®10% if renal function deteriorates4
† Monitor the patient carefully throughout the infusion. Certain adverse reactions may be related to the rate of infusion. Slowing or stopping the infusion usually allows the symptoms to disappear promptly. Once the symptoms subside, the infusion may then be resumed at a lower rate.4
octagam®10% is a proven choice for DM patients 4
1. Goyal, N. A. (2019) Immune-Mediated Myopathies. Continuum 25, 1564–1585.
2. D’Silva, K. M. et al. (2021) Persistent premature mortality gap in dermatomyositis and polymyositis: A United Kingdom general population-based cohort study. Rheumatology 60, 2653–26602.
3. Glaubitz S. et al. (2020). Therapeutic advances in musculoskeletal disease 12, 1759720X19886494.
4. Octagam®10%. Summary of Product Characteristics. May 2021.
5. USA Product Information /Package Insert- OCTAGAM 10% (fda.gov) Octapharma USA Inc. June 2021.
6. Aggarwal, R. et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. An International Myositis Assessment and Clinical Studies Group/ Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann. Rheum. Dis. 76, 792–801
7. Aggarwal, R. et al. Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam®10% in patients with dermatomyositis (“ProDERM Study”). Medicine (Baltimore) 100, e23677
8. Ahmed S, Chen KL, Werth VP. The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review. Semin Arthritis Rheum. 2020;50(3):458-462.
This is an international website for octagam® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website.